Serial biotech entrepreneur Langer talks launch strategy

In a piece for Nature Biotechnology, serial biotech entrepreneur and MIT professor Robert Langer shared some of his experiences in launching more than two dozen biotechs over the past 26 years. "I started my first company in 1987 because I realized it was an effective path for transforming science into life-saving and life-improving inventions. Startup companies provide one means for accomplishing ends that interested me: creating products that have a positive effect on human health. I did this first with a colleague, but through the years I have also started many companies with students and postdocs in my MIT lab." Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.